The Valley Desk

ArticleJournal for immunotherapy of cancerPublished

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source

Publication record

Type
Article
Venue
Journal for immunotherapy of cancer
Published
Subject terms
Animals; Mice, Transgenic; Humans; Mice; Melanoma; Disease Models, Animal; Peptides; Antineoplastic Agents; Antibodies, Monoclonal; Tumor Microenvironment; CTLA-4 Antigen; Ipilimumab
PubMed ID
38164757
PubMed Central ID
PMC10729150
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal